
About Alzheon
Alzheon is a Healthcare company based in Framingham (United States) founded in 2013. Oral inhibitors of amyloid aggregation for Alzheimers treatment are developed. Alzheon has raised $274.04 million across 13 funding rounds from investors including NIH, HHS and Ally Bridge Group. Alzheon offers products and services including valiltramiprosate and ALZ-801. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is Future X Beta s.r.o. Its competitors include T3D Therapeutics, Longeveron and Totus Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Alzheon was founded in 2013 and is headquartered in Framingham, United States. Focus is placed on the biotechnology sector, specifically the development of oral therapeutics for Alzheimers disease. The lead candidate, ALZ-801, a prodrug of tramiprosate, is advanced as an inhibitor targeting amyloid aggregation and neurotoxicity. Clinical operations are conducted to address key pathological hallmarks of the disease.
- Headquarters Framingham, United States
- SectorsHealthcare
- Website alzheon.com
- Social LinkedIn X
- Legal Name Future X Beta S.R.O.
- Total Equity Funding$274.04M (USD)
in 13 rounds
- Latest Funding Round$78.8M (USD), Series E
Aug 2026
- InvestorsNIH
& 3 more
Products & Services of Alzheon
Alzheon offers a comprehensive portfolio of products and services, including valiltramiprosate and ALZ-801.
Investigational oral drug targeting amyloid oligomers in Alzheimer's disease
Oral treatment for early Alzheimer's in APOE4 carriers
Funding Insights of Alzheon
Alzheon has successfully raised a total of $274.04M across 13 strategic funding rounds. The most recent funding activity was a Series E round of $78.8 million completed in August 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $274.04M
- Total Rounds 13
- Last Round Series E β $78.8M
- Investors Count 4
Latest 10 of 13 funding rounds of Alzheon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2026 | $78.8M | Series E | β | β | β |
| Jun 2024 | $100M | Series E | β | Alerce Medical Technology Partners | β |
| Feb 2024 | $1M | Series D | β | β | β |
| Apr 2022 | $50M | Series D | β | β | β |
| Sep 2020 | $2.43M | Series B | β | β | β |
| Aug 2020 | Grant | β | β | ||
| Aug 2020 | $51.19M | Grant | β | β | |
| Jan 2020 | $6.16M | Series B | β | β | β |
| Sep 2018 | $19.8M | Series B | β | β | β |
| May 2017 | $5.3M | Series A | β | β | β |
4 investors in total: 4 institutional.
Investors in Alzheon
Alzheon has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Ally Bridge Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and hedge fund investments in healthcare are managed. | ally-bridge.com | Hong Kong, China | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Alzheon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alzheon
38 people are tracked at Alzheon (12 in leadership, 25 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Aidan Power | Chief Development Officer | Leadership |
Martin Tolar | Founder, President & CEO | Leadership |
Kenneth Mace | Chief Financial Officer | Leadership |
Susan Abushakra | CMO | Leadership |
Patrick Kesslak | VP, Clinical Development & Medical Affairs | Leadership |
Erwan De Naurois | VP, Finance | Leadership |
Stacy Trudeau | Senior Director Of Finance | Leadership |
Yasemin Khakian | Chief Of Staff | Leadership |
Luke Tolar | Senior Director, Business Development | Leadership |
Earvin Liang | VP, Clinical Development | Leadership |
Adem Albayrak | Chief Data Officer | Leadership |
Stacey Kaufusi | Vice President, Quality | Head Of Quality | Leadership |
Diane K. Jorkasky | Director | Board & advisors |
Jordan Heller | Director | Board & advisors |
Christopher Noel Dunn | Non Executive Director | Board & advisors |
Neil Flanzraich | Executive Chairman | Board & advisors |
Kaj Blennow | Scientific Advisor | Board & advisors |
Jakub Hort | Scientific Advisor | Board & advisors |
Serge Gauthier | Scientific Advisor | Board & advisors |
Steven Jacobsen | Scientific Advisor | Board & advisors |
18 more people are available in the full profile.
Complete people profiles for Alzheon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Alzheon
3 dated milestones of Alzheon across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Alzheon is founded.
- Funding First funding round.
- Funding Latest funding round, Series E, of $78.8M.
Competitors of Alzheon
Alzheon has 3 listed competitors in our database, 3 of them funded. They include T3D Therapeutics, Longeveron and Totus Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| t3dtherapeutics.com | 2013 | Durham, United States | $33.02M | Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed. | ||
| longeveron.com | 2014 | Miami, United States | $1.05M | 23 | Cellular therapies for aging-related and life-threatening conditions are developed. | |
| totusmedicines.com | 2019 | Cambridge, United States | $106M | 23 | Genome-scale drug discovery platform is provided for treating multiple diseases. |
Detailed competitors of Alzheon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Alzheon
The website of Alzheon (alzheon.com) receives about 4.8K visits a month.
- Monthly visits4.8K
▼ 2% vs previous month
Websites whose visitors overlap most with Alzheon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
leqembihcp.com | leqembihcp.com | 100% | #2,737,943 | β |
Top companies in Neurology
3 companies that operate in the same segment as Alzheon (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alzheon
Complete news archive for Alzheon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alzheon
Alzheon was founded in 2013.
Alzheon is headquartered in Framingham, United States. It is registered at Framingham, Massachusetts, United States.
Alzheon is a funded company, having raised a total of $274.04M across 13 funding rounds to date. The company's 1st funding round was a Series A of $5.3M, raised on Oct 2013.
Alzheon was founded in 2013 and is headquartered in Framingham, United States. Focus is placed on the biotechnology sector, specifically the development of oral therapeutics for Alzheimers disease. The lead candidate, ALZ-801, a prodrug of tramiprosate, is advanced as an inhibitor targeting amyloid aggregation and neurotoxicity. Clinical operations are conducted to address key pathological hallmarks of the disease.
Alzheon's top competitors include Longeveron, Totus Medicines and T3D Therapeutics.
Alzheon offers valiltramiprosate and ALZ-801.
Alzheon has 4 investors. Key investors include NIH, HHS, Ally Bridge Group, and Alerce Medical Technology Partners.
Alzheon operates through Future X Beta S.R.O..
